U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT07515209) titled 'A Clinical Study of HH-006 in Untreated Chronic Hepatitis B Virus Infected Patients' on March 25.
Brief Summary: This is a randomized, double-blind, placebo-controlled Phase I dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of multiple ascending doses (120 mg, 240 mg, 480 mg SC, QWx5) of HH-006 in untreated chronic HBV patients. Each cohort includes 12 participants (9 active, 3 placebo), with dose progression approved by a Safety Review Committee. Participants are monitored through 24 weeks post-dose. The study design allows for adjustments based on emerging data.
Study Start Dat...